Privium Fund Management’s Ionis Pharmaceuticals IONS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$21.8M Buy
290,024
+49,200
+20% +$3.88M 4.53% 7
2025
Q4
$19.1M Sell
240,824
-8,070
-3% -$608K 3.51% 7
2025
Q3
$16.3M Sell
248,894
-18,700
-7% -$913K 2.93% 10
2025
Q2
$10.7M Hold
267,594
2.31% 9
2025
Q1
$8.07M Buy
267,594
+800
+0.3% +$26.2K 2.1% 8
2024
Q4
$9.33M Buy
266,794
+16,050
+6% +$600K 2.11% 12
2024
Q3
$10M Buy
250,744
+3,477
+1% +$162K 2.5% 11
2024
Q2
$11.2M Buy
247,267
+20,274
+9% +$832K 2.85% 9
2024
Q1
$9.84M Buy
226,993
+9,500
+4% +$453K 2.63% 11
2023
Q4
$11.5M Sell
217,493
-11,000
-5% -$527K 3.2% 7
2023
Q3
$10.4M Buy
228,493
+2,000
+0.9% +$82.5K 3.08% 8
2023
Q2
$9.31M Buy
226,493
+43,720
+24% +$1.68M 2.68% 13
2023
Q1
$6.53M Buy
182,773
+33,966
+23% +$1.28M 2.19% 17
2022
Q4
$5.56M Hold
148,807
2.11% 16
2022
Q3
$6.59M Sell
148,807
-31,300
-17% -$1.32M 2.39% 11
2022
Q2
$6.67M Hold
180,107
2.21% 14
2022
Q1
$6.67M Sell
180,107
-450,092
-71% -$14.7M 1.47% 23
2021
Q4
$19.2M Buy
+630,199
New +$19.8M 3.82% 7

Other funds holding IONS

Privium Fund Management's IONS Position: Q1 2026 in Review

Privium Fund Management increased its Ionis Pharmaceuticals (IONS) stake by 20% in Q1 2026, buying an estimated $3.88M and bringing the position to 290,024 shares worth $21.8M. The position accounts for 4.53% of the portfolio, ranked #7.

Privium Fund Management first reported a position in IONS in Q4 2021 and has held it in 18 quarters since. 493 funds tracked by Wall St. Rank hold IONS as of Q1 2026.

  • Privium Fund Management held 290,024 shares of Ionis Pharmaceuticals worth $21.8M as of Q1 2026.
  • Privium Fund Management bought 49,200 Ionis Pharmaceuticals shares in Q1 2026, an estimated $3.88M.
  • Ionis Pharmaceuticals made up 4.53% of Privium Fund Management's portfolio in Q1 2026, its #7 holding.
  • Privium Fund Management first reported a position in Ionis Pharmaceuticals in Q4 2021 and has held it in 18 quarters since.
  • 493 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2026.

Based on Privium Fund Management's 13F filing for Q1 2026, filed 5 May 2026.